TickerGuard
Buy Day today: Neutral (53) Mixed market breadth · no major macro event

Omada Health, Inc. Common Stock (OMDA)

Healthcare Health Information Services
19.80 $
+0.8% vs. previous close
Closing price · As of: 31. Jul 2026
🔔 Watch stock

Stock Watch

Stock Watch will tell you what changes at Omada Health, Inc. Common Stock.

Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.

Appears in These Scanners

This stock currently matches 5 of our scanner strategies — each hit links to the scanner.

Quality & Balance Sheet

Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. View all scanners

Trading Day

Previous Close
19.70$
Open
19.80$
Day High
20.00$
Day Low
19.50$
Volume
1,522,492shares

Key levels of the most recently completed trading day — not a live quote.

52-Week Range

52-Week Low 52-Week High
10.90 $ 26.80 $
02/11/2026 10/28/2025

Current price 19.80 $ — 56% of the range above the low.

Lowest and highest closing price over the last 52 weeks. The marker shows where the current price sits within that range: close to the high speaks for strength, close to the low for weakness.

Basics

Market Cap
0.0$B
Shares Outstanding
59Mio.
Float
78.6%
Beta

Performance

Perf. 1M
21.60%
Perf. 3M
82.80%
Perf. 6M
36.10%
YTD Performance (%)
16.00%
52-Week-High Distance
-29.8%
Perf. 1Y
13.24%
Perf. 5Y
-2.11%
Perf. Since Inception
4.42%

Technical Indicators

MA 38 Days
20.70$
MA 50 Days
19.90$
MA 200 Days
17.10$
RSI (14)
38.7
Volatility 30 Days
44.6%
Volatility 250 Days
57.1%

Calculated from the price history · as of 08/03/2026

Valuation

P/E
Forward P/E
769.2
PEG
P/B
4.6
P/S
EV/EBITDA
1,364.4
Price/FCF

Profitability

Gross Margin
66.3%
EBIT Margin
Net Margin
-2.2%
Return on Equity
-4.3%
Return on Assets
-2.4%

Balance Sheet & Safety

Equity Ratio
Debt/Equity
fortress balance sheet
Altman Z″
6.11
Piotroski
3 out of 9

Growth

Sales Growth Last Quarter
0.00%
EPS Growth Last Quarter
Sales Growth (Year)
53.24%
Forward Sales Growth
19.93%
Forward EPS Growth
45.90%

Dividend

This stock currently pays no dividend.

Quality & Screener

Stage
3
RS Rating
61
EPS Rating
50
Piotroski
3 out of 9
Fundamental Rating
B (65 out of 100)
fortress balance sheet
Altman Z″
6.11

AI Rating

Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available. How the Rating Is Built

Growth Score

8 of 10 Growth gem

Ten checks against the annual reports — each one passed counts a point.

  • Revenue grows by more than 15% a year over three years 42.9% passed
  • More than 10% revenue growth is expected for the coming year 19.9% passed
  • Share count grows by less than 3% a year 1.6% passed
  • Revenue growth plus cash-flow margin add up to at least 40 ("Rule of 40") 59.8% passed
  • Gross margin at 40% or higher and without meaningful erosion 65.7% passed
  • Goodwill from acquisitions does not grow faster than revenue 4.3% passed
  • Net debt below twice EBITDA 222 m net cash passed
  • Operating cash flow covers the profits of the last three years 62 m passed
  • Return on capital at 15% or higher, or up versus two years ago -5.2% failed
  • Insiders hold at least 10% or are net buyers 2.3% failed

A criterion without figures counts neither as passed nor as failed; a score is only produced from 7 judgeable criteria upwards. Source: fundamental data. All ten criteria in detail

Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.

Analysts & Price Target

Current Price 19.80 $
Price Target (average) 22.92 $

The price target sits 15.8% above the current price.

Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.

Next Reporting Date

6. Aug 2026 · after the close · Q2 2026
Expected Earnings per Share
-0.01 $

Expected date of the next quarterly or annual figures. Dates do shift occasionally — only the invitation issued by the company is binding.

Revenue & Profit

Cash Flow

Balance Sheet

Margins

Per Share

Click the chart or tab into it, then use ← and → to step through the periods.

None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.

These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.

The figures could not be loaded right now.

Sales Per Quarter ($M)
2024: Q4 · 48.0 $M Q4 2025: Q1 · 55.0 $M Q1 2025: Q2 · 61.4 $M Q2 2025: Q3 · 68.0 $M Q3 2025: Q4 · 75.8 $M Q4 2026: Q1 · 78.0 $M Q1

Source: fundamental data

Compare with other stocks →

Quarterly Figures

Quarterly Figures
Quarter EPS (Earnings Per Share) EPS YoY (%) Sales ($M) Sales YoY (%) Net Margin (%) OCF ($M) FCF ($M)
2024: Q4 -0.15 48 47.40 -17.20 -7 -8
2025: Q1 -0.17 55 56.60 -17.20 -16 -17
2025: Q2 -0.09 61 48.90 -8.70 3 3
2025: Q3 -0.06 68 49.50 -4.70 10 10
2025: Q4 0.09 76 58.10 6.80 21 21
2026: Q1 -0.05 78 42.00 -3.80 -12 -12
What Do These Terms Mean?
EPS (Earnings Per Share):
Quarterly profit divided by the total share count — how much of the profit works out to a single share.
YoY (Year over Year):
Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
Sales:
All revenue for the quarter, before any costs are deducted — the top line of the income statement.
Net Margin:
What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
OCF (Operating Cash Flow):
The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
FCF (Free Cash Flow):
Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.

About the Company

Omada Health, Inc. zusammen mit seiner Tochtergesellschaft Physera, Inc.

CEO Insider Trades (12 Mo.)selling own stock
Employees943
HeadquartersSouth San Francisco, CA
Websiteomadahealth.com
IPO Date6. Jun 2025

Management

Management
Name Title Birth Year
Sean P. Duffy Co-Founder, CEO & Director 1984
Wei-Li Shao President 1971
Steven L. Cook Chief Financial Officer 1986
Lauren Fix Senior Vice President of Corporate Strategy & Operations
Craig Gracey Chief Accounting Officer 1991
Sunil Kayiti Chief Technology Officer
Allan Kells Vice President of Investor Relations
Nathan Salha General Counsel
Nancy Vitale Chief People Officer 1971
Jennifer Becker Chief Care Delivery Operating Officer

Executives per the latest required filings; titles kept in their original language. Source: fundamental data.

Insider Transactions

Insider Transactions
Date Person Role Type Shares Price Value
15. Jul 2026 Cook Steven L. Chief Financial Officer Sell 11,750 24.01 282,174
15. Jul 2026 Cook Steven L. Chief Financial Officer Sell 400 24.00 9,600
15. Jul 2026 Cook Steven L. Chief Financial Officer Other 12,150 8.28 100,602
13. Jul 2026 Gracey Craig Chief Accounting Officer Sell 1,041 24.00 24,984
13. Jul 2026 Gracey Craig Chief Accounting Officer Other 1,041 6.57 6,839
13. Jul 2026 Cook Steven L. Chief Financial Officer Sell 600 24.01 14,406
13. Jul 2026 Cook Steven L. Chief Financial Officer Sell 5,200 24.00 124,800
13. Jul 2026 Cook Steven L. Chief Financial Officer Other 5,800 8.28 48,024
7. Jul 2026 Cook Steven L. Chief Financial Officer Sell 12,337 23.09 284,840
7. Jul 2026 Cook Steven L. Chief Financial Officer Other 694 7.68 5,330

Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character.

View all insider transactions →

Chart

Interactive price chart (TradingView).

Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?